Genotoxic colibactin mutational signature in colorectal cancer is associated with clinicopathological features, specific genomic alterations and better survival.
Peter GeorgesonRobert S SteinfelderTabitha A HarrisonBernard J PopeSyed H ZaidiConghui QuYi LinJihoon E JooKhalid MahmoodMark ClendenningRomy WalkerElom K AglagoSonja I BerndtHermann BrennerPeter T CampbellYin CaoAndrew T ChanJenny Chang-ClaudeNiki DimouKimberly F DohenyDavid A DrewJane C FigueiredoAmy J FrenchSteven GallingerMarios GiannakisGraham G GilesEllen L GoodeStephen B GruberAndrea GsurMarc J GunterSophia HarlidMichael HoffmeisterLi HsuWen-Yi HuangJeroen R HuygheJoAnn E MansonVictor MorenoNeil MurphyRami NassirChristina C NewtonJonathan A NowakMireia Obón-SantacanaShuji OginoRish K PaiNikos PapadimitrouJohn D PotterRobert E SchoenMingyang SongWei SunAmanda E TolandQuang M TrinhKostas TsilidisTomotaka UgaiCaroline Y UmFinlay A MacraeChristophe RostyThomas J HudsonIngrid M WinshipAmanda I PhippsMark A JenkinsUlrike PetersDaniel D BuchananPublished in: medRxiv : the preprint server for health sciences (2023)
SBS88-positivity, a biomarker of colibactin-induced DNA damage, can identify a novel subtype of CRC characterized by recurrent somatic mutations, copy number alterations and better survival. These findings provide new insights for treatment and prevention strategies for this subtype of CRC.